[I-131-LYM-1 MoAb radioimmunotherapy and LYM-1 MoAb immunotherapy in implanted nude mice model].
Experimental studies of I-131-LYM-1 MoAb radioimmunotherapy (RIT) and LYM-1 MoAb immunotherapy (IT) were performed in 23 implanted nude mice model. 1 x 10(7) human B-cell lymphoma cells (Raji Burkitt's cells) were injected subcutaneously into the thigh. Three weeks later, they were divided into four groups: Group A (N = 6), as control group; Group B (N = 5), received LYM-1 MoAb 60 micrograms, as IT group; Group C (N = 7), received I-131-LYM-1 MoAb 120 mu ci; and Group D (N = 5), received I-131-LYM-1 MoAb 240 mu ci. Radioimaging was performed on day 7,8,9 postinjection. Tumor growth after 30 days was as follows: Group A, from 0.040 +/- 0.091 CM3 to 7.638 +/- 5.925; Group B, from 0.326 +/- 0.315 to 4.498 +/- 2.572; Group C, from 0.632 +/- 0.449 to 3.330 +/- 4.875; Group D, from 0.490 +/- 0.531 to 2.352 +/- 2.188. When converted to Relative Increase of Tumor Volume (Times-X): The tumor in Group A increased 4346.19 X; in Group B 312.68 X; in Group C 15.94 X; and in Group D 8.36 X. Significant differences were noted between Groups A and B (p less than 0.05), A and C (p less than 0.025), A and D (p less than 0.025), B and C (p less than 0.025) and B and D (p less than 0.025). The difference between Group C and D was insignificant (p greater than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)